Jiawei Zhao

Hangzhou Sanjing Biotech Co., Ltd. Founded in 2022, Hangzhou Sanjing Biotech Co., Ltd. focuses on the research, development and services of nanobodies, providing innovative pharmaceutical companies with high-quality nanobody products and early-stage discovery CRO services. The company is equipped with a comprehensive nanobody discovery platform, concentrating on the early discovery of nanobodies to provide source innovation support for clients’ new drug R&D. To date, Sanjing Biotech has validated more than 100 popular drug targets, established partnerships with multiple pharmaceutical R&D enterprises, and successfully delivered numerous nanobody early-stage R&D projects. Sanjing Biotech operates high-standard modern laboratories and advanced instrument platforms, with a strict quality control system in place. Our R&D team is led by PhDs from Peking University and Zhejiang University, with years of deep expertise in nanobodies and recombinant proteins. Supported by strong academic backgrounds and industrial experience, we collaborate with top universities to continuously drive technological breakthroughs. With excellent quality, efficient delivery, and flexible cooperation models, we are committed to empowering new drug R&D and accelerating the translation and application of innovative achievements.